Genenta to Present at Upcoming Scientific and Investor Conferences
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) — Genenta Science S.p.A. (NASDAQ:GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells towards a permanent self-vaccination against cancer, will present at several upcoming scientific and investor conferences.
Related news for (GNTA)
- Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
- FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
- Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients